Pharming Analyst Price Targets - Benzinga

SPY776.53 QQQ753.29+0.76%BTC/USD82,891.97+1.47%DIA511.95 GLD383.00 TLT77.71−0.21%

Pharming Group

PHARNASDAQ

Trade with Public

Trade with Public

$9.47

-0.18-1.87%

Last update: Oct 2, 7:07 PM

$10.00

0.353.67%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Pharming Analyst Price Targets - Benzinga

Pharming Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pharming (PHAR).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

4Buy

Consensus RatingBuy# Analysts4Avg. Consensus PT$34Upside to Avg. PT+237.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 22, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Sep 14, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Aug 3, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$37→$38
Apr 10, 2026	Canaccord Genuity	Whitney Ijem	Initiate	Buy	$37
Mar 24, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Mar 13, 2026	Oppenheimer	Jeff Jones	PT Cut	Outperform	$42→$41
Mar 21, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Mar 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Mar 14, 2025	Oppenheimer	Michael Carrier	PT Raise	Outperform	$30→$39
Mar 14, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 17, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 16, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 11, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Dec 9, 2024	Jefferies	Lucy Codrington	Initiate	Buy	$14
Oct 28, 2024	Oppenheimer	Michael Carrier	PT Cut	Outperform	$31→$30
Oct 24, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Oct 15, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Oct 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Sep 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37
Aug 1, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$37

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37

Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.

Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Pharming, Lowers Price Target to $41

Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the price target from $42 to $41.

Benzinga Newsdesk